The success of the NETTER-1 trial with lutetium-177 (177Lu)-DOTATATE in patients with midgut neuroendocrine tumors (Strosberg et al., 2017), and the promising results of 177Lu-prostate specific-membrane antigen (177Lu-PSMA) ligand treatments in patients with prostate cancer (von Eyben et al., 2018) have given this field further positive momentum. This evidence concerns the gene FOLH1 and prostate cancer.